Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 23, 46 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches

Current Pharmaceutical Design, 20(32): 5212-5217.

Author(s): Hamendra Singh Parmar, Mahesh Kumar Bhinchar, Muskan Bhatia, Nikita Chordia, Ishan Raval, Digvijay Singh Chauhan, E. Manivannan, Rameshwar Jatwa and Anil Kumar.

Affiliation: School of Biotechnology, Devi Ahilya University, Takshashila Campus, khandwa Road, Indore- 452001, M.P., India.


Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition


Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 32
First Page: 5212
Last Page: 5217
Page Count: 6
DOI: 10.2174/1381612820666140318114832
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 20174th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science